Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of a novel somatostatin analog (SSA) for the treatment of diseases resulting from hormone-active tumors, such as Acromegaly, Neuroendocrine and Gastroenteropancreatic Tumors, Cushings Disease and Diabetic Retinopathy.
